Polaryx Therapeutics, Inc. (PLYX)

NASDAQ: PLYX · USD

$1.78

+0.05 (+2.9%)· Recorded snapshot

Market cap	88.7M
Net income (ttm)	-6.8M
EPS (ttm)	-$0.15
Shares out	49.8M
Volume	10,669

Market data

Price

Recent price action with selectable time range.

Financial snapshot

Net income (ttm): -6.8M
EPS (ttm): -$0.15
Market cap: 88.7M

Ticker	Name	Market cap	P/E	P/S	ROIC	5Y rev CAGR	1Y total return	Rating
EXAS	Exact Sciences Corp	—	—	—	—	—	—	احتفاظ

Calendar

Next earnings

Upcoming earnings date and setup when available.

Upcoming

DateLoading

Window—

EPS estimate—

Revenue estimate—

Sector percentile context

Refreshed 2026-11-04 20:55 UTC

Forward P/En/a

P25 n/aP50 n/aP75 n/a

Trailing P/En/a

P25 n/aP50 n/aP75 n/a

ROE-96.6

P25 n/aP50 n/aP75 n/a

ROIC-46

P25 n/aP50 n/aP75 n/a

Benchmarks · 1M

All PLYX indicators

Market & fundamental data

Available fields

146

Groups with data

Currency

USD

Showing 146 of 146 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Amount currency	USD
CIK code	0002075320
Company name	Polaryx Therapeutics, Inc.
Country	United States
Country code	US
CUSIP number	73110F100
Earnings date	2026-11-18
Earnings time	bmo
Employees	11
Enterprise value	$77.2M
Exchange	NASDAQ
Financial currency	USD
Financial report date	2026-06-30
First seen	2026-05-09
Fiscal year end	December
Founded	2014
Industry	Biotechnology
Is primary listing	Yes
Is SPAC	No
ISIN number	US73110F1003
Last 10-K release date	2026-03-24
Last earnings date	2026-08-13
Last refreshed	2026-11-04
Last stock split type	Never
Market cap	$88.7M
Market cap category	Micro-Cap
Next earnings date	2026-11-18
Options	No
Price	$1.78
Price currency	USD
Sector	Healthcare
SIC code	2834
Stock price date	2026-11-04
Symbol	PLYX
U.S. state	New Jersey
Website	https://polaryx.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Earnings yield	-8.18%
FCF / EV yield	-7.78%
FCF yield	-6.74%
P/B ratio	7.88x
Price / tangible book value	7.88x
Sector forward P/E	23.32x
Sector P/E	49.47x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
Profit per employee	$-622,636
ROA	-42.52%
ROCE	-47.75%
ROE	-96.56%
ROIC	-46.02%

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
EPS growth years	1
Net income growth years	1
Revenue growth years	0

Financial statements

Income-statement and cash-flow amounts, totals and per share.

Metric	Value
EBIT	$-5.2M
EPS	$-0.15
FCF per share	$-0.12
Financing cash flow	$14M
Free cash flow	$-5.8M
Free cash flow minus SBC	$-6.4M
Net cash flow	$8.2M
Net income	$-6.8M
Operating cash flow minus SBC	$-6.4M
Operating income	$-5.2M
Stock-based compensation	$632,000

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Book value per share	$0.22
Debt / equity	0
Long-term assets	$0
Long-term liabilities	$0
Net cash (debt)	$11.5M
Net cash / market cap	13.38%
Net cash growth	249.33%
Net debt / equity	-1.06
Piotroski F-Score	2
Shareholders' equity	$10.9M
Tangible book value	$10.9M
Tangible book value per share	$0.22
Total assets	$11.8M
Total cash	$11.5M
Total debt	$0
Total liabilities	$873,000

Liquidity

Current-asset coverage and working-capital efficiency metrics.

Metric	Value
Current assets	$11.8M
Current liabilities	$873,000
Current ratio	13.53
Net working capital	$-603,000
Quick ratio	13.22
Working capital	$10.9M

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Buyback yield / dilution	-13.11%
Dividend yield	0%
Shareholder yield	-13.11%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
150-day SMA	$2.82
1D price change	2.89%
1M price change	-14.9%
1M total return	-14.9%
1W price change	-6.35%
1W total return	-6.35%
20-day SMA	$1.89
3M price change	-19.18%
3M total return	-19.18%
50-day SMA	$1.99
52-week high	$48.91
52-week high date	2026-02-02
52-week low	$1.69
52-week low date	2026-11-03
6M price change	-63.73%
6M total return	-63.73%
All-time high	$48.91
All-time high date	2026-02-02
All-time low	$1.69
All-time low date	2026-11-03
Average true range (ATR)	$0.11
Average volume	28.2K
Beta (1Y)	-1.18
Change from 52-week high	-96.36%
Change from 52-week low	5.33%
Change from all-time high	-96.38%
Change from all-time low	4.73%
Change from open	-0.56%
Day's gap	3.47%
Dollar volume	$18,991
High price	$1.85
Low price	$1.76
Monthly RSI	0
Open price	$1.79
Position in 52-week range	22.22%
Premarket change	5.2%
Premarket close	$1.73
Premarket price	$1.82
Premarket volume	605
Previous close	$1.73
Price vs 150-day SMA	-37.26%
Price vs 20-day SMA	-6.25%
Price vs 50-day SMA	-11.14%
Relative volume	0.38
RSI	36.43
Sharpe ratio	-1.16
Sortino ratio	-1.67
Volume	10.7K
Weekly RSI	36.61

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	7.2M
Float percentage	14.38%
Shares change (QoQ)	2.24%
Shares change (YoY)	13.11%
Shares held by insiders	30.88%
Shares held by institutions	4.63%
Shares outstanding	49.8M
Short % of float	1.65%
Short % of shares	0.24%
Short ratio	3.5 days

Deeper analysis on PLYX

14 sections in the full report · jump straight to what you need

Forecast

Base and Bull forecast paths with report-date return framing.

→

Valuation

Fair-value bridge, DCF, owner earnings, and peer multiples.

→

Sensitivity

Cost-of-equity and terminal-growth stress table.

→

Risks

Kill scenarios, soft-pass flags, and downside catalysts.

→

Earnings

Next earnings setup and beat / inline / miss thresholds.

→

Position sizing

Entry, exit, conviction, and quarterly monitoring rules.

→

Financials

Revenue, margins, cash flow, and balance-sheet context.

→

Peers

Relative valuation and profitability against the cohort.

→

Moat

Economic-profit evidence and competitive advantage risk.

→

Industry cycle

Sector phase, capital cycle, and secular tailwinds.

→

Frequently asked questions

About this PLYX report

Is a complete PLYX research report available?

No complete published report is available for Polaryx Therapeutics, Inc. (PLYX) on this page. Market-directory data, when present, is not a substitute for a validated stock analysis.

Polaryx Therapeutics, Inc. (PLYX)

Price

Financial snapshot

Fair-value bridge

Latest news · PLYX

Valuation

Profitability

Balance sheet

Trading

Next earnings

Sector percentile context

All PLYX indicators

Profile and market data

Valuation

Profitability

Growth

Financial statements

Financial strength

Liquidity

Dividends and buybacks

Performance and technicals

Ownership and float

Deeper analysis on PLYX

Frequently asked questions